Larimar Therapeutics, Inc.
LRMR
$2.86
$0.217.93%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 4.66M | 4.45M | 5.02M | 3.90M | 3.71M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 31.29M | 18.26M | 24.60M | 16.73M | 14.16M |
| Operating Income | -31.29M | -18.26M | -24.60M | -16.73M | -14.16M |
| Income Before Tax | -28.82M | -15.50M | -21.63M | -14.65M | -12.99M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -28.82M | -15.50M | -21.63M | -14.65M | -12.99M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -28.82M | -15.50M | -21.63M | -14.65M | -12.99M |
| EBIT | -31.29M | -18.26M | -24.60M | -16.73M | -14.16M |
| EBITDA | -31.22M | -18.19M | -24.51M | -16.65M | -14.08M |
| EPS Basic | -0.45 | -0.24 | -0.34 | -0.27 | -0.30 |
| Normalized Basic EPS | -0.28 | -0.15 | -0.21 | -0.17 | -0.19 |
| EPS Diluted | -0.45 | -0.24 | -0.34 | -0.27 | -0.30 |
| Normalized Diluted EPS | -0.28 | -0.15 | -0.21 | -0.17 | -0.19 |
| Average Basic Shares Outstanding | 63.81M | 63.81M | 63.80M | 53.55M | 43.91M |
| Average Diluted Shares Outstanding | 63.81M | 63.81M | 63.80M | 53.55M | 43.91M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |